Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Seres Therapeutics Inc (NQ: MCRB ) 0.8600 -0.0142 (-1.62%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Seres Therapeutics Inc < Previous 1 2 3 4 5 6 7 8 9 Next > MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q2 2024 August 13, 2024 MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace MCRB Investigation Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Seres Therapeutics, Inc. Assets Is Fair to Shareholders August 09, 2024 From Halper Sadeh LLC Via Business Wire 12 Health Care Stocks Moving In Monday's Intraday Session June 10, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's Intraday Session June 07, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session May 09, 2024 Via Benzinga Seres Therapeutics's Earnings: A Preview March 04, 2024 Via Benzinga Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session June 07, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Intraday Session May 08, 2024 Via Benzinga MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q1 2024 May 08, 2024 MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Why Upstart Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session May 08, 2024 Via Benzinga Nasdaq Down Over 50 Points; Uber Posts Q1 Loss May 08, 2024 Via Benzinga Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates May 08, 2024 From Seres Therapeutics, Inc. Via Business Wire Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 06, 2024 From Seres Therapeutics, Inc. Via Business Wire Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024 May 06, 2024 From Seres Therapeutics, Inc. Via Business Wire Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT April 09, 2024 From Seres Therapeutics, Inc. Via Business Wire Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 28, 2024 From Seres Therapeutics, Inc. Via Business Wire Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 19, 2024 From Seres Therapeutics, Inc. Via Business Wire Emerson Electric To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Wednesday March 06, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga Gold Price Alert: Gold Spot Prices Just Hit a Record High Today March 05, 2024 Investors in gold are excited on Tuesday as the spot price of the precious metal hit a recent high of $2,113.28 per ounce during a rally. Via InvestorPlace MCRB Stock Earnings: Seres Therapeutics Beats EPS for Q4 2023 March 05, 2024 MCRB stock results show that Seres Therapeutics beat analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates March 05, 2024 From Seres Therapeutics, Inc. Via Business Wire Earnings Scheduled For March 5, 2024 March 05, 2024 Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. Via Benzinga Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024 February 28, 2024 From Seres Therapeutics, Inc. Via Business Wire Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference February 27, 2024 From Seres Therapeutics, Inc. Via Business Wire Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz February 26, 2024 From Seres Therapeutics, Inc. Via Business Wire Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 17, 2024 From Seres Therapeutics, Inc. Via Business Wire Why Is Microbiome-Based Seres Therapeutics Stock Trading Higher Today? January 09, 2024 Seres Therapeutics Inc (NASDAQ: MCRB) received FDA Fast Track Designation for SER-155, an investigational oral, cultivated microbiome therapeutic designed to prevent GI-associated bacterial infections... Via Benzinga Exposures Product Safety Dow Tumbles Over 200 Points; US Trade Gap Narrows In November January 09, 2024 U.S. stocks traded lower this morning, with the Dow Jones falling more than 200 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.63% to 37,445.51 while the NASDAQ fell... Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Tuesday's Pre-Market Session January 09, 2024 Via Benzinga Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155 January 09, 2024 From Seres Therapeutics, Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.